termsTerm
Neuroendocrine tumour grade (Ki-67) and WHO classification
How fast the tumour cells are dividing, measured by Ki-67 staining, separates slow-growing neuroendocrine tumours from aggressive neuroendocrine carcinomas and decides the treatment.
WHO 2019/2022: well-differentiated NET grade 1 (Ki-67 <3%), grade 2 (3-20%), grade 3 (>20%, well-differentiated); poorly differentiated neuroendocrine carcinoma (NEC, small- or large-cell) is a separate lineage treated like small-cell lung cancer. Grade drives choice among somatostatin analogues, PRRT, targeted therapy and chemotherapy.
Pathology: what this kind of term is about · animated schematic, not to scale
Category
Pathology
Pages like this
not linked directly; found by shared links- IdeaThe pathology lab triggers a trial referral the day a rare cancer is diagnosed
Shares Histopathology & immunohistochemistry, Neuroendocrine tumours.
- TechnologySomatostatin receptor PET (68Ga/64Cu-DOTATATE)
- ProductActinium-225 DOTATATE
- IdeaA same-week expert second opinion for every rare cancer diagnosis
Shares Histopathology & immunohistochemistry, Neuroendocrine tumours.
- ProductEtoposide
- TargetDLL3
- ProductTarlatamab